
Lupin Ltd
NSE:LUPIN

Lupin Ltd
Net Income
Lupin Ltd
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Lupin Ltd
NSE:LUPIN
|
Net Income
â‚ą32.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income
â‚ą72.3B
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Cipla Ltd
NSE:CIPLA
|
Net Income
â‚ą63.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income
â‚ą128.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Net Income
â‚ą56.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income
â‚ą25.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Lupin Ltd
Glance View
In the bustling landscape of the global pharmaceutical industry, Lupin Ltd. stands as a testament to the transformative power of innovation and strategic foresight. Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin embarked on its journey with a clear vision: to deliver high-quality drugs at affordable prices. Over the years, it has adeptly navigated the complex world of pharmaceuticals to become a formidable player in the generics market. Its success is built on a robust portfolio that includes a diverse range of generic and branded formulations across many therapeutic segments such as cardiovascular, diabetology, asthma management, and anti-tuberculosis. The company prioritizes intensive research and development, paving the way for both the introduction of new generics and the development of advanced drug delivery systems. Such focus ensures Lupin maintains a competitive edge in both established markets like the United States and emerging markets across Asia and Africa. The company’s financial engine is powered largely by its extensive manufacturing and distribution capabilities, which are strategically positioned across the globe to maximize efficiency and meet demand. With state-of-the-art facilities in India supplemented by strategic acquisitions and partnerships overseas, Lupin produces a wide array of active pharmaceutical ingredients (APIs) and finished dosages, allowing it to capture value across different stages of the drug supply chain. This vertically integrated model not only enhances profit margins but also provides the agility to respond quickly to market shifts. Furthermore, Lupin's strategic emphasis on biosimilars and specialty drugs reinforces its commitment to innovation, unlocking new revenue streams amid growing global healthcare demands. As Lupin continues to expand its footprint, it remains anchored in its mission to improve healthcare outcomes, embodying a legacy where profitability harmoniously aligns with purpose.

See Also
What is Lupin Ltd's Net Income?
Net Income
32.8B
INR
Based on the financial report for Dec 31, 2024, Lupin Ltd's Net Income amounts to 32.8B INR.
What is Lupin Ltd's Net Income growth rate?
Net Income CAGR 1Y
94%
Over the last year, the Net Income growth was 94%.